AU2011263478B2 - Injectable flowable composition comprising buprenorphine - Google Patents

Injectable flowable composition comprising buprenorphine Download PDF

Info

Publication number
AU2011263478B2
AU2011263478B2 AU2011263478A AU2011263478A AU2011263478B2 AU 2011263478 B2 AU2011263478 B2 AU 2011263478B2 AU 2011263478 A AU2011263478 A AU 2011263478A AU 2011263478 A AU2011263478 A AU 2011263478A AU 2011263478 B2 AU2011263478 B2 AU 2011263478B2
Authority
AU
Australia
Prior art keywords
buprenorphine
flowable composition
implant
metabolite
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011263478A
Other languages
English (en)
Other versions
AU2011263478A1 (en
Inventor
Richard L. Norton
Andrew Watkins
Mingxing Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indivior UK Ltd
Original Assignee
Indivior UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011263478(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indivior UK Ltd filed Critical Indivior UK Ltd
Publication of AU2011263478A1 publication Critical patent/AU2011263478A1/en
Application granted granted Critical
Publication of AU2011263478B2 publication Critical patent/AU2011263478B2/en
Assigned to INDIVIOR UK LIMITED reassignment INDIVIOR UK LIMITED Request to Amend Deed and Register Assignors: RB PHARMACEUTICALS LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2011263478A 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine Active AU2011263478B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1009549.5 2010-06-08
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
PCT/GB2011/051057 WO2011154724A2 (en) 2010-06-08 2011-06-06 Compositions

Publications (2)

Publication Number Publication Date
AU2011263478A1 AU2011263478A1 (en) 2013-01-10
AU2011263478B2 true AU2011263478B2 (en) 2015-01-22

Family

ID=42471306

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011263478A Active AU2011263478B2 (en) 2010-06-08 2011-06-06 Injectable flowable composition comprising buprenorphine

Country Status (32)

Country Link
US (1) US8921387B2 (https=)
EP (3) EP2579874B1 (https=)
JP (2) JP5986072B2 (https=)
KR (1) KR101865689B1 (https=)
CN (1) CN103079544B (https=)
AU (1) AU2011263478B2 (https=)
BR (1) BR112012031290A2 (https=)
CA (1) CA2801676C (https=)
CL (1) CL2012003462A1 (https=)
CO (1) CO6670529A2 (https=)
CY (1) CY1120761T1 (https=)
DK (2) DK3360538T3 (https=)
ES (2) ES2656938T3 (https=)
FI (1) FI3360538T3 (https=)
GB (2) GB2481018B (https=)
HR (1) HRP20180118T1 (https=)
HU (1) HUE038275T2 (https=)
IL (2) IL223488A (https=)
LT (1) LT2579874T (https=)
MX (1) MX339209B (https=)
MY (1) MY171625A (https=)
NO (1) NO2579874T3 (https=)
NZ (1) NZ604026A (https=)
PL (1) PL2579874T3 (https=)
PT (1) PT2579874T (https=)
RS (1) RS56820B1 (https=)
RU (1) RU2607498C2 (https=)
SG (1) SG186200A1 (https=)
SI (1) SI2579874T1 (https=)
SM (1) SMT201800038T1 (https=)
WO (1) WO2011154724A2 (https=)
ZA (1) ZA201209233B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
WO2013126552A1 (en) * 2012-02-21 2013-08-29 Auburn University Buprenorphine nanoparticle composition and methods thereof
KR102196741B1 (ko) 2012-04-17 2020-12-30 퍼듀 퍼머 엘피 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
NZ704012A (en) * 2012-07-26 2017-09-29 Camurus Ab Opioid formulations
EP3791861A1 (en) 2012-07-26 2021-03-17 Camurus AB Opioid formulations
WO2014093907A1 (en) * 2012-12-13 2014-06-19 A.P. Pharma, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
CN105358129A (zh) * 2013-03-15 2016-02-24 赫伦治疗有限公司 聚原酸酯和质子惰性溶剂的组合物
US9393211B2 (en) * 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
WO2018048460A1 (en) 2014-04-21 2018-03-15 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
ES2837149T3 (es) * 2014-04-21 2021-06-29 Heron Therapeutics Inc Composiciones de un poliortoéster y un excipiente de ácido orgánico
CA2946281C (en) 2014-04-21 2022-12-13 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
LT3137081T (lt) 2014-04-28 2018-02-26 Orphomed, Inc. Buprenorfino dimeras ir jo naudojimas gydant virškinamojo trakto sutrikimus
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
NZ731309A (en) * 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
US10786515B2 (en) 2015-08-03 2020-09-29 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
EP4374861A3 (en) 2015-11-16 2024-08-07 MedinCell S.A. A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
TWI743193B (zh) 2016-09-13 2021-10-21 昱展新藥生技股份有限公司 丁基原啡因緩釋製劑
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
EP3638240A2 (en) 2017-06-16 2020-04-22 Indivior UK Limited Methods to treat opioid use disorder
EP3743072B1 (en) 2018-01-22 2023-10-25 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
BR112020016576A2 (pt) * 2018-05-11 2020-12-15 Alar Pharmaceuticals Inc. Formulações injetáveis de ação prolongada e formas cristalinas de derivados de buprenorfina
EP3863712A4 (en) 2018-10-11 2022-07-20 Indivior UK Limited BUPRENORPHINE USED TO TREAT RESPIRATORY DEPRESSION
US12403291B2 (en) * 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform
CN118831057A (zh) * 2023-04-25 2024-10-25 深圳善康医药科技股份有限公司 丁丙诺啡植入剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043432A2 (en) * 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
ATE317690T1 (de) 1994-04-08 2006-03-15 Qlt Usa Inc Flüssige zusammensetzungen zur arzneistoffabgabe
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
CA2487577C (en) * 2002-05-31 2014-11-18 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
AU2004219595A1 (en) * 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
BRPI0516308A2 (pt) * 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
CA2586846C (en) * 2004-11-10 2013-12-31 Qlt Usa Inc. A stabilized polymeric delivery system
HUE025842T2 (en) 2007-02-15 2016-04-28 Tolmar Therapeutics Inc Poly (lactide / glycolide) with reduced fracture properties and methods for producing polymers
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043432A2 (en) * 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GRAVES, R.A. et al. "In Vitro Dissolution Method for Evaluation of Buprenorphine In Situ Gel Formulation: A Technical Note" AAPS PharmSciTech (2007) Vol.8 No.3 Article 62 pages E1 to E4 *

Also Published As

Publication number Publication date
FI3360538T3 (fi) 2023-03-22
ES2939612T3 (es) 2023-04-25
EP4218720A1 (en) 2023-08-02
EP3360538B1 (en) 2023-02-15
KR101865689B1 (ko) 2018-06-08
NO2579874T3 (https=) 2018-06-09
WO2011154724A9 (en) 2012-08-16
GB201413064D0 (en) 2014-09-03
MX2012014335A (es) 2013-03-05
SI2579874T1 (en) 2018-03-30
EP2579874B1 (en) 2018-01-10
GB2513267A (en) 2014-10-22
GB2481018A (en) 2011-12-14
DK2579874T3 (da) 2018-01-29
HRP20180118T1 (hr) 2018-03-09
ES2656938T3 (es) 2018-03-01
LT2579874T (lt) 2018-02-12
IL254417A0 (en) 2017-11-30
GB2481018B (en) 2015-03-18
CA2801676C (en) 2018-08-07
CY1120761T1 (el) 2019-12-11
AU2011263478A1 (en) 2013-01-10
JP2013533230A (ja) 2013-08-22
GB201009549D0 (en) 2010-07-21
HUE038275T2 (hu) 2018-10-29
US8921387B2 (en) 2014-12-30
RS56820B1 (sr) 2018-04-30
SG186200A1 (en) 2013-01-30
BR112012031290A2 (pt) 2016-11-01
EP3360538A1 (en) 2018-08-15
US20130210853A1 (en) 2013-08-15
JP2016155865A (ja) 2016-09-01
IL223488A (en) 2017-10-31
CN103079544B (zh) 2017-06-09
CL2012003462A1 (es) 2013-04-01
GB2513267B (en) 2015-03-18
PT2579874T (pt) 2018-01-29
CA2801676A1 (en) 2011-12-15
NZ604026A (en) 2015-01-30
MY171625A (en) 2019-10-21
PL2579874T3 (pl) 2018-05-30
ZA201209233B (en) 2014-04-30
RU2607498C2 (ru) 2017-01-10
RU2012157244A (ru) 2014-07-20
KR20130135026A (ko) 2013-12-10
CO6670529A2 (es) 2013-05-15
CN103079544A (zh) 2013-05-01
JP5986072B2 (ja) 2016-09-06
WO2011154724A2 (en) 2011-12-15
JP6251774B2 (ja) 2017-12-20
MX339209B (es) 2016-04-15
DK3360538T3 (da) 2023-03-06
EP2579874A2 (en) 2013-04-17
SMT201800038T1 (it) 2018-03-08
WO2011154724A3 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
AU2011263478B2 (en) Injectable flowable composition comprising buprenorphine
US10592168B1 (en) Injectable flowable composition comprising buprenorphine
US20230135427A1 (en) Sustained delivery formulations of risperidone compound
US8975270B2 (en) Injectable flowable composition comprising buprenorphine
HK40097172A (en) Injectable flowable composition comprising buprenorphine
HK1184056B (en) Injectable flowable composition comprising buprenorphine
HK1184056A (en) Injectable flowable composition comprising buprenorphine

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)